newsfilter
← Latest News
Business Wire·

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential ImmunoPrecise (NASDAQ:IPA), a leader in AI-driven biotherapeutics, provides a significant update